While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good ...

One Zelienople child survived a serious health scare after coming down with respiratory syncytial virus in late January. The ...

Vulnerable and elderly Australians are missing out on protection against respiratory syncytial virus (RSV) because many can’t ...

Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.

More than 86,000 recorded cases of respiratory syncytial virus in 2024 were in children younger than four years old.

The French drugmaker said it had entered a mandate with an “investment service provider”, with the purchase occurring between ...

The AstraZeneca deal brought US rights to mature respiratory syncytial virus drug Synagis as well as RSV drug Beyfortus (now launched), expanding Sobi's US exposure dramatically. Gamifant ...

A vaccine designed to help protect babies from the respiratory syncytial virus (RSV) is now free during pregnancy. RSV is the ...

As we head into the peak of 2025 RSV season, parents are once again facing an uptick in cases, with health experts warning ...

Two RSV vaccines were approved for use in Australia ... are picking up the tab for Sanofi-Aventis’ nirsevimab (sold as Beyfortus) for infants. This is widely used, and funded, in the US and ...